FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial

Annals of Oncology

Volumn 23, Issue 10, 2012, Pages 2552-2561

  Ladoire, S ^a,b   Mignot, G ^b   Dalban, C ^c   Chevriaux, A ^a,b   Arnould, L ^a   Rebe C ^a,b   Apetoh, L ^a,b   Boidot, R ^a   Penault Llorca, F ^d   Fumoleau, P ^a   Roche H ^e   Spielmann, M ^f   Levy, C ^g   Lortholary, A ^h   Eichler, F ⁱ   Mesleard, C ^j   Bonnetain, F ^c   Ghiringhelli, F ^a,b  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c EA 4184   (France)

^d CENTRE JEAN PERRIN   (France)

^e INSTITUT CLAUDIUS REGAUD   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g CENTRE FRANÇOIS BACLESSE   (France)

^h CENTRE PAUL PAPIN   (France)

ⁱ HÔPITAL CIVIL   (France)

^j UNICANCER   (France)

more..

Author keywords

Adjuvant; Anthracycline; Breast cancer; FOXP3

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84867121868     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds028     Document Type: Article

References (30)

1. Sakaguchi S, Ono M, Setoguchi R et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006; 212: 8-27.
2. Karanikas V, Speletas M, Zamanakou M et al. Foxp3 expression in human cancer cells. J Transl Med 2008; 6: 19.
3. Hinz S, Pagerols-Raluy L, Oberg HH et al. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 2007; 67: 8344-8350.
4. Ebert LM, Tan BS, Browning J et al. The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res 2008; 68: 3001-3009.
5. Merlo A, Casalini P, Carcangiu ML et al. FOXP3 expression and overall survival in breast cancer. J Clin Oncol 2009; 27: 1746-1752.
6. Zuo T, Liu R, Zhang H et al. FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J Clin Invest 2007; 117: 3765-3773.
7. Zuo T, Wang L, Morrison C et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 2007; 129: 1275-1286.
8. Ladoire S, Arnould L, Mignot G et al. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 2011; 125: 65-72.
9. Jung DJ, Jin DH, Hong SW et al. Foxp3 expression in p53-dependent DNA damage responses. J Biol Chem 2010; 285: 7995-8002.
10. Roche H, Fumoleau P, Spielmann M et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006; 24: 5664-5671.
11. McShane LM, Altman DG, Sauerbrei W et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005; 23: 9067-9072.
12. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387.
13. Tao R, de Zoeten EF, Ozkaynak E et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007; 13: 1299-1307.
14. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061.
15. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330-336.
16. Liu Y, Wang Y, Li W et al. Activating transcription factor 2 and c-Jun-mediated induction of FoxP3 for experimental therapy of mammary tumor in the mouse. Cancer Res 2009; 69: 5954-5960.
17. Tsihlias J, Kapusta L, Slingerland J. The prognostic significance of altered cyclindependent kinase inhibitors in human cancer. Annu Rev Med 1999; 50: 401-423.
18. Catzavelos C, Bhattacharya N, Ung YC et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997; 3: 227-230.
19. Porter PL, Malone KE, Heagerty PJ et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997; 3: 222-225.
20. Davidovich S, Ben-Izhak O, Shapira M et al. Over-expression of Skp2 is associated with resistance to preoperative doxorubicin-based chemotherapy in primary breast cancer. Breast Cancer Res 2008; 10: R63.
21. Carrano AC, Eytan E, Hershko A et al. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999; 1: 193-199.
22. Sutterluty H, Chatelain E, Marti A et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1999; 1: 207-214.
23. Marchion DC, Bicaku E, Daud AI et al. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther 2005; 4: 1993-2000.
24. Kim MS, Blake M, Baek JH et al. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003; 63: 7291-7300.
25. Kurz EU, Wilson SE, Leader KB et al. The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol Cancer Ther 2001; 1: 121-131.
26. Marchion DC, Bicaku E, Daud AI et al. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res 2005; 65: 3815-3822.
27. Tsai SC, Valkov N, Yang WM et al. Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet 2000; 26: 349-353.
28. Marchion DC, Bicaku E, Turner JG et al. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clin Cancer Res 2005l; 11: 8467-8475.
29. Munster P, Marchion D, Bicaku E et al. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res 2009; 15: 2488-2496.
30. Munster P, Marchion D, Bicaku E et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007; 25: 1979-1985.